EUVIMEDOpdag EUVIMED
Multizentrische Studie

Treatment Delay and HPV Status on OPSCC With Upfront Surgery: Analysis of National Cancer Database

Milind Vasudev iD, Elaine Martin, Madelyn I Frank, Leo L T Meller, Yarah M Haidar

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.699 ↗

At a glance

Multizentrische Studie in Otolaryngology–Head and Neck Surgery, 2024. Written by Milind Vasudev and 4 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA. Major MEDLINE topics: Oropharyngeal Neoplasms, Papillomavirus Infections, Time-to-Treatment, Databases, Factual. Cited 3 times so far (Crossref); 41 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Evaluate the effect of treatment delay on survival in human papillomavirus (HPV)‐positive and HPV‐negative oropharyngeal squamous cell carcinoma (OPSCC) patients undergoing primary surgical resection. Study Design Retrospective cohort study using the 2010‐2017 National Cancer Database.

Setting

Multicenter database study.

Methods

Patients >18 years old with OPSCC and known HPV status, treated surgically with or without postoperative radiation/chemotherapy were included. Two cohorts based on HPV status were grouped by time to treatment initiation (T D‐TI , ≤30, 31‐60, ≥61 days) and surgery to radiotherapy (T S‐RT , ≤42, 43‐66, ≥67 days). Univariate, Kaplan‐Meier, and multivariate analyses assessed correlations between demographic and clinical factors with overall survival in treatment delay groups.

Results

Included were 1643 HPV‐positive OPSCC patients and 391 HPV‐negative OPSCC patients. No associations between survival and gender, age, race, insurance, or radiotherapy length were observed. Regardless of HPV status, larger tumor size (>2 cm) and lymphovascular invasion predicted worse survival. HPV negative patients with >4 lymph nodes involved had 2.5× greater mortality risk ( P = .039). Robotic surgery was associated with improved survival only in HPV positive patients (hazard ratio [HR]: 0.41, P < .001). In HPV positive patients, higher T D‐TI related to lower mean survival, although this was not significant on multivariate analysis. HPV negative patients with >42 days of T S‐RT had decreased survival (43‐66 days, HR 1.63, P = .049; ≥67 days, HR 2.10, P = .032).

Conclusion

Longer T S‐RT was associated with lower overall survival in HPV negative patients. Treatment delay was not associated with survival in HPV positive OPSCC according to multivariate analysis. These findings enhance knowledge about treatment delay effects in OPSCC, aiding providers in decisions and patient communication.

Subjects

MeSH terms (MEDLINE)

Oropharyngeal NeoplasmsPapillomavirus InfectionsTime-to-TreatmentDatabases, FactualHumansMaleFemaleRetrospective StudiesMiddle AgedAgedUnited StatesSurvival RateTreatment Delay

Author keywords

NCDBcomplicationshead and neckradiation

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA.
  • School of Medicine, University of California, San Diego, La Jolla, California, USA.

ORCID profiles: Milind Vasudev

Cite

APA

Vasudev, M., Martin, E., Frank, M. I., Meller, L. L. T., & Haidar, Y. M. (2024). Treatment Delay and HPV Status on OPSCC With Upfront Surgery: Analysis of National Cancer Database. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.699

Vancouver

Vasudev M, Martin E, Frank MI, Meller LLT, Haidar YM. Treatment Delay and HPV Status on OPSCC With Upfront Surgery: Analysis of National Cancer Database. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.699

BibTeX
@article{Vasudev2024,
  author = {Vasudev, Milind and Martin, Elaine and Frank, Madelyn I and Meller, Leo L T and Haidar, Yarah M},
  title = {Treatment Delay and HPV Status on OPSCC With Upfront Surgery: Analysis of National Cancer Database},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.699}
}
Start for free →